Scarab Genomics

Executive Summary

Scarab Genomics is a mature biotechnology firm based in Madison, Wisconsin, with a unique synthetic biology platform centered on its proprietary Clean Genome® E. coli strains. These strains, stripped of non-essential genetic elements, offer superior performance for recombinant protein and nucleic acid production, reducing byproducts and increasing yield. The company also produces CRM197, a non-toxic mutant of diphtheria toxin widely used as a carrier protein in conjugate vaccines against bacterial pathogens. Operating since 2000, Scarab Genomics has established itself as a reliable supplier to the pharmaceutical and biotech industries, with its technologies enabling more efficient and cost-effective manufacturing of biologic drugs and vaccine components. The global market for recombinant proteins and conjugate vaccines is expanding, driven by demand for biologics and new vaccine development. Scarab Genomics’ Clean Genome technology provides a competitive edge in protein expression, while its CRM197 offering taps into the growing vaccine market. The company is well-positioned to benefit from trends toward synthetic biology and continuous manufacturing. Given its established track record and niche focus, Scarab Genomics represents a stable investment opportunity with moderate growth potential. Key upcoming catalysts include new partnerships for CRM197 supply, product line expansions, and potential government funding for synthetic biology initiatives.

Upcoming Catalysts (preview)

• Q3 2026Partnership with pharmaceutical company for CRM197 supply40% success
• Q4 2026Expansion of Clean Genome® product line50% success
• Q2 2026Grant or government funding for synthetic biology research30% success